Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All aspirin studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchAspirinAspirin (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality 40% Improvement Relative Risk ARDS 37% Aspirin for COVID-19  Ali et al.  ICU PATIENTS Is very late treatment with aspirin beneficial for COVID-19? Retrospective 1,190 patients in Egypt Lower mortality (p<0.0001) and ARDS (p=0.0011) with aspirin c19early.org Ali et al., Egyptian J. Anaesthesia, Oct 2022 Favors aspirin Favors control

Effect of Aspirin Use on clinical Outcome among Critically Ill Patients with COVID-19

Ali et al., Egyptian Journal of Anaesthesia, doi:10.1080/11101849.2022.2139104
Oct 2022  
  Post
  Facebook
Share
  Source   PDF   All   Meta
Aspirin for COVID-19
24th treatment shown to reduce risk in August 2021
 
*, now known with p = 0.000087 from 73 studies, recognized in 2 countries.
Lower risk for mortality and progression.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,100+ studies for 60+ treatments. c19early.org
Retrospective 1,190 ICU patients in Egypt, showing lower mortality with aspirin treatment. 150mg daily.
risk of death, 39.6% lower, RR 0.60, p < 0.001, treatment 152 of 660 (23.0%), control 202 of 530 (38.1%), NNT 6.6.
risk of ARDS, 37.4% lower, RR 0.63, p = 0.001, treatment 74 of 660 (11.2%), control 95 of 530 (17.9%), NNT 15.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Ali et al., 31 Oct 2022, retrospective, Egypt, peer-reviewed, 3 authors. Contact: rania_m_ismail@yahoo.com.
This PaperAspirinAll
Effect of Aspirin Use on clinical Outcome among Critically Ill Patients with COVID- 19
Rania M Ali, Ayman I Tharwat, Heba A Labib
Egyptian Journal of Anaesthesia, doi:10.1080/11101849.2022.2139104
Background: Critically ill COVID-19 patients are at risk of developing major complications with high mortality rate. Aspirin might have favorable effects in severe COVID-19 via various mechanisms besides inhibition of platelet aggregation. The role of aspirin as adjuvant therapy in critically ill patients with COVID-19 has not been studied. In this study, we investigated the correlation between aspirin use and the clinical outcome in critically ill COVID-19 patients. Methods: This is a retrospective cohort observational study of critically ill COVID-19 Egyptian patients. Participants were divided into two groups: patients who received aspirin, 150 mg per day orally, upon admission to the intensive care unit, and those who did not. The primary outcome in this study was the shift to invasive ventilatory support. Results: A total of 1190 patients were involved in the study, 660 patients received aspirin, while 530 patients did not. Among aspirin group compared to non-aspirin group, invasive ventilatory support, DVT, PE, stroke, ACS, ARDS, AKI, septic shock, and mortality were less frequent, and the differences were significant except for ACS, AKI, and septic shock. Major bleeding was non-significantly more frequent. The length of ICU stay was significantly longer among non-survivors, and shorter among survivors. The variations between the two groups were significant among subgroups ≥40 or 60. Conclusions: In critically ill patients with COVID-19, aspirin has the potential role as an adjuvant therapeutic, lowering the risk of mechanical ventilation, thromboembolic events, ARDS, and ICU mortality. Patients older than 40 years were a significant category that might benefit from aspirin.
Disclosure statement No potential conflict of interest was reported by the author(s).
References
Azboy, Barrack, Thomas, Aspirin and the prevention of venous thromboembolism following total joint arthroplasty: commonly asked questions, Bone Joint J
Becattini, Agnelli, Schenone, Aspirin for preventing the recurrence of venous thromboembolism, N Engl J Med
Bradbury, Lawler, Stanworth, Investigators, Effect of antiplatelet therapy on survival and organ support-free days in critically ill patients with COVID-19: a randomized clinical trial, JAMA
Brighton, Eikelboom, Mann, Low-dose aspirin for preventing recurrent venous thromboembolism, N Engl J Med
Chow, Khanna, Kethireddy, Aspirin use is associated with decreased mechanical ventilation, intensive care unit admission, and in-hospital mortality in hospitalized patients with coronavirus disease, Anesth Analg, doi:10.1213/ANE.0000000000005292
Chow, Rahnavard, Gomberg-Maitland, Association of early aspirin use with in-hospital mortality in patients with moderate COVID-19, JAMA Netw open
Guan, Ni, Hu, Clinical characteristics of coronavirus disease 2019 in China, N Engl J Med
Ikonomidis, Andreotti, Economou, Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin, Circulation
Ismail, Bensasi, Taha, Characteristics and outcome of critically ill patients with coronavirus disease-2019 (COVID-19) pneumonia admitted to a tertiary care center in the United Arab Emirates during the first wave of the SARS-CoV-2 pandemic. A retrospective analysis, PLoS One
Kor, Carter, Park, Effect of aspirin on development of ARDS in at-risk patients presenting to the emergency department: the LIPS-a randomized clinical trial, JAMA
Liang, Liang, Ou, Development and validation of a clinical risk score to predict the occurrence of critical illness in hospitalized patients with COVID-19, JAMA Intern Med
Middeldorp, Coppens, Van Haaps, Incidence of venous thromboembolism in hospitalized patients with COVID-19, J Thromb Haemost
Osborne, Veigulis, Arreola, Association of mortality and aspirin prescription for COVID-19 patients at the veterans health administration, PLoS One
Panka, De Grooth, Spoelstra-De Man, Prevention or treatment of ards with aspirin: a review of preclinical models and meta-analysis of clinical studies, Shock
Rapkiewicz, Mai, Carsons, Megakaryocytes and platelet-fibrin thrombi characterize multi-organ thrombosis at autopsy in COVID-19: a case series, EClinicalMedicine
Shaw, Bradbury, Abrams, COVID-19 and immunothrombosis: emerging understanding and clinical management, Br J Haematol
Varga, Flammer, Steiger, Endothelial cell infection and endotheliitis in COVID-19, Lancet
Voruganti, Bassareo, Calcaterra, Does aspirin save lives in patients with COVID-19?, Heart
Wijaya, Andhika, Huang, The effects of aspirin on the outcome of COVID-19: a systematic review and meta-analysis, Clin Epidemiol Glob Heal
{ 'DOI': '10.1080/11101849.2022.2139104', 'ISSN': ['1110-1849'], 'URL': 'http://dx.doi.org/10.1080/11101849.2022.2139104', 'alternative-id': ['10.1080/11101849.2022.2139104'], 'assertion': [ { 'label': 'Peer Review Statement', 'name': 'peerreview_statement', 'order': 1, 'value': 'The publishing and review policy for this title is described in its Aims & ' 'Scope.'}, { 'URL': 'http://www.tandfonline.com/action/journalInformation?show=aimsScope&journalCode=teja20', 'label': 'Aim & Scope', 'name': 'aims_and_scope_url', 'order': 2, 'value': 'http://www.tandfonline.com/action/journalInformation?show=aimsScope&journalCode=teja20'}, { 'group': {'label': 'Publication History', 'name': 'publication_history'}, 'label': 'Received', 'name': 'received', 'order': 0, 'value': '2022-09-03'}, { 'group': {'label': 'Publication History', 'name': 'publication_history'}, 'label': 'Revised', 'name': 'revised', 'order': 1, 'value': '2022-10-08'}, { 'group': {'label': 'Publication History', 'name': 'publication_history'}, 'label': 'Accepted', 'name': 'accepted', 'order': 2, 'value': '2022-10-17'}, { 'group': {'label': 'Publication History', 'name': 'publication_history'}, 'label': 'Published', 'name': 'published', 'order': 3, 'value': '2022-10-31'}], 'author': [ { 'affiliation': [ { 'name': 'Department of Anesthesia, Intensive Care and Pain Management, ' 'Faculty of Medicine, Ain Shams University, Cairo, Egypt'}], 'family': 'Ali', 'given': 'Rania M.', 'sequence': 'first'}, { 'affiliation': [ { 'name': 'Department of Anesthesia, Intensive Care and Pain Management, ' 'Faculty of Medicine, Ain Shams University, Cairo, Egypt'}], 'family': 'Tharwat', 'given': 'Ayman I.', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'Department of Anesthesia, Intensive Care and Pain Management, ' 'Faculty of Medicine, Ain Shams University, Cairo, Egypt'}], 'family': 'Labib', 'given': 'Heba A.', 'sequence': 'additional'}], 'container-title': 'Egyptian Journal of Anaesthesia', 'container-title-short': 'Egyptian Journal of Anaesthesia', 'content-domain': {'crossmark-restriction': True, 'domain': ['www.tandfonline.com']}, 'created': {'date-parts': [[2022, 11, 1]], 'date-time': '2022-11-01T06:30:42Z', 'timestamp': 1667284242000}, 'deposited': { 'date-parts': [[2022, 11, 1]], 'date-time': '2022-11-01T06:30:43Z', 'timestamp': 1667284243000}, 'indexed': {'date-parts': [[2022, 11, 2]], 'date-time': '2022-11-02T05:01:48Z', 'timestamp': 1667365308444}, 'is-referenced-by-count': 0, 'issue': '1', 'issued': {'date-parts': [[2022, 10, 31]]}, 'journal-issue': {'issue': '1', 'published-print': {'date-parts': [[2022, 12, 31]]}}, 'language': 'en', 'license': [ { 'URL': 'http://creativecommons.org/licenses/by/4.0/', 'content-version': 'unspecified', 'delay-in-days': 0, 'start': { 'date-parts': [[2022, 10, 31]], 'date-time': '2022-10-31T00:00:00Z', 'timestamp': 1667174400000}}], 'link': [ { 'URL': 'https://www.tandfonline.com/doi/pdf/10.1080/11101849.2022.2139104', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'member': '301', 'original-title': [], 'page': '629-635', 'prefix': '10.1080', 'published': {'date-parts': [[2022, 10, 31]]}, 'published-online': {'date-parts': [[2022, 10, 31]]}, 'published-print': {'date-parts': [[2022, 12, 31]]}, 'publisher': 'Informa UK Limited', 'reference': [ {'DOI': '10.1111/bjh.17664', 'doi-asserted-by': 'publisher', 'key': 'cit0001'}, {'DOI': '10.1371/journal.pone.0251687', 'doi-asserted-by': 'publisher', 'key': 'cit0002'}, {'DOI': '10.1111/jth.14888', 'doi-asserted-by': 'publisher', 'key': 'cit0003'}, {'DOI': '10.1136/heartjnl-2021-320255', 'doi-asserted-by': 'publisher', 'key': 'cit0004'}, {'DOI': '10.1213/ANE.0000000000005292', 'doi-asserted-by': 'publisher', 'key': 'cit0005'}, { 'DOI': '10.1001/jamanetworkopen.2022.3890', 'doi-asserted-by': 'publisher', 'key': 'cit0006'}, {'DOI': '10.1016/j.eclinm.2020.100434', 'doi-asserted-by': 'publisher', 'key': 'cit0007'}, {'DOI': '10.1016/S0140-6736(20)30937-5', 'doi-asserted-by': 'publisher', 'key': 'cit0008'}, {'DOI': '10.1016/j.cegh.2021.100883', 'doi-asserted-by': 'publisher', 'key': 'cit0009'}, {'DOI': '10.1161/01.CIR.100.8.793', 'doi-asserted-by': 'publisher', 'key': 'cit0010'}, {'DOI': '10.1016/S0140-6736(21)01825-0', 'doi-asserted-by': 'publisher', 'key': 'cit0011'}, {'DOI': '10.1001/jama.2016.6330', 'doi-asserted-by': 'publisher', 'key': 'cit0012'}, {'DOI': '10.1097/SHK.0000000000000745', 'doi-asserted-by': 'publisher', 'key': 'cit0013'}, {'DOI': '10.1371/journal.pone.0246825', 'doi-asserted-by': 'publisher', 'key': 'cit0014'}, {'DOI': '10.1001/jama.2022.2910', 'doi-asserted-by': 'publisher', 'key': 'cit0015'}, {'DOI': '10.1056/NEJMoa1114238', 'doi-asserted-by': 'publisher', 'key': 'cit0016'}, {'DOI': '10.1056/NEJMoa1210384', 'doi-asserted-by': 'publisher', 'key': 'cit0017'}, { 'DOI': '10.1302/0301-620X.99B11.BJJ-2017-0337.R2', 'doi-asserted-by': 'publisher', 'key': 'cit0018'}, {'DOI': '10.1056/NEJMoa2002032', 'doi-asserted-by': 'publisher', 'key': 'cit0019'}, { 'DOI': '10.1001/jamainternmed.2020.2033', 'doi-asserted-by': 'publisher', 'key': 'cit0020'}], 'reference-count': 20, 'references-count': 20, 'relation': {}, 'resource': {'primary': {'URL': 'https://www.tandfonline.com/doi/full/10.1080/11101849.2022.2139104'}}, 'score': 1, 'short-title': [], 'source': 'Crossref', 'subject': ['Anesthesiology and Pain Medicine'], 'subtitle': [], 'title': 'Effect of Aspirin Use on clinical Outcome among Critically Ill Patients with COVID- 19', 'type': 'journal-article', 'update-policy': 'http://dx.doi.org/10.1080/tandf_crossmark_01', 'volume': '38'}
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit